Venture Investors


Novartis Venture Fund leads $7M round for developer of adult ADHD medication

A Boston-area startup emerged from the depths of stealth mode today touting a $7 million financing round that will help it move toward clinical trials of a drug that would treat attention-deficit/hyperactivity disorder (ADHD) without addictive side effects. EB-1020, Neurovance Inc.’s lead drug candidate for ADHD, acts on three neurotransmitters: norepinephrine, dopamine and serotonin. Other […]


Akebia Therapeutics gets thumbs up from clinical trial, investors

Updated 6:47 p.m. Small molecule discovery and development company Akebia Therapeutics Inc. reported positive results from a second Phase 1 clinical trial of its anemia drug, as well as the second closing of a $16 million financing round announced almost a year ago, boosting the round to $17 million. Startup Akebia is racing to the […]


Cellectar completes patient enrollment in Phase 1 cancer trial

Radiopharmaceuticals company Cellectar Inc. has enrolled the last of eight patients in a Phase 1 trial of its cancer-treating drug candidate. The trial is designed to measure drug safety and dosimetry of Cellectar’s lead compound, called CLR1404. Dosimetry refers to the measurement of doses, which also allows investigators to understand how a drug will affect […]

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.


Cardiovascular biopharma Akebia takes additional funding to develop 2 drugs

The company stated it raised additional money to ensure the development of two of its drugs. Akebia plans later this year to start Phase I clinical trials on an oral medication designed to create new red blood cells in anemia patients. In addition, it wants to establish a human clinical proof of concept for a second drug that prevents vascular leak syndrome, in which blood components leak out of veins and into other systems -- a side effect of some cancer treatments.